Free Trial

Organovo Q4 2023 Earnings Report

Organovo logo
$0.36 -0.01 (-3.28%)
(As of 12/20/2024 05:31 PM ET)

Organovo EPS Results

Actual EPS
-$0.85
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Organovo Earnings Headlines

Organovo Holdings Inc
Trump’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Organovo Holdings Gains Approval for Key Strategic Moves
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat

Upcoming Earnings